Royalty Pharma plc RPRX

NAS: RPRX | ISIN: GB00BMVP7Y09 19:00

27,46 USD (+0,68%)

(+0,68%) 19:00

Grafiek Royalty Pharma plc

Grafiek Royalty Pharma plc

1 dag1d 0,68%
1 week1w -3,26%
1 maand1m -1,31%
3 maanden3m -9,39%
6 maanden6m 1,95%
1 jaar1j -17,75%
5 jaar5j -38,30%

vrijdag 14 juni 2024

Uitbetaling dividend: 0,21 USD per aandeel. Ex-dividend op 16/05/2024.

Royalty Pharma plc in het nieuws

Toon enkel gratis nieuws

9 januari 2023 · Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness · Persbericht

13 juli 2022 · Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value · Persbericht

30 juni 2022 · Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma · Persbericht

29 maart 2022 · Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment · Persbericht

17 februari 2021 · Royalty Pharma Reports Q4 2020 and Full-Year Results · Persbericht

22 januari 2021 · Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021 · Persbericht

8 januari 2021 · Royalty Pharma Announces 13% Dividend Increase · Persbericht

7 januari 2021 · Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12 · Persbericht

Profiel Royalty Pharma plc

Gezondheidstechnologie

Medicinale en botanische productie

Website: www.royaltypharma.com

Hoofdzetel: New York, New York Verenigde Staten

CEO: Pablo Gerardo Legorreta

Werknemers: 92

Aandelen Royalty Pharma plc

Beurswaarde: 12,30 miljard USD

Effecten: 450,98 miljoen

Winst per aandeel (12 maand): PLUS

Koers-winstverhouding: PLUS

Beta: 0,62

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe